91插插视频,91熟女露脸视频,精品国产综合一区,跪舔内射人妻

Date: 23-March-2019  
Source:  Guangdong Tencent News

TAEST16001 of Xiangxue has been the first TCR-T IND (Investigational New Drug) in China approved by NMPA (National Medical Products Administration).

With independent intellectual property rights, Xiangxue Life Sciences has established a platform to develop cell-based therapies that take advantage of the unique attributes of TCR mediated target recognition. As first product of company, TAEST16001 reaches the international advanced level. Being considered of the highly effective technology for tumor vaccination, TCR-T has shown the potential to improve cure rate and to save lives of patients with malignant tumor.

廣州市香雪制藥股份有限公司子公司廣東香雪精準醫(yī)療技術(shù)有限公司向國家藥品監(jiān)督管理局提交的TAEST16001注射液新藥臨床注冊申請已獲得國內(nèi)首個TCR-T臨床試驗許可。

香雪精準已建立TCR-T完整的技術(shù)平臺及工藝，具有完整的自主知識產(chǎn)權(quán)，TAEST16001注射液是香雪精準研發(fā)管線的第一個產(chǎn)品，達到了國際先進水平。特異性T細胞受體免疫治療技術(shù)（TCR-T）是目前在腫瘤免疫治療領(lǐng)域具有顯著療效的先進技術(shù)，可實現(xiàn)疾病的個體化精準治療，大大提高腫瘤的治愈率，從而有望從根本上治愈惡性腫瘤這一頑疾。